Reprogramming FGFR isoform specificity in FGF2 by deep mutational scanning

Yuga Okada1, Jumpei Morimoto1, Shinsuke Sando1,2

  • 1Department of Chemistry and Biotechnology, The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-8656 Japan ssando@chembio.t.u-tokyo.ac.jp.

Chemical Science
|August 6, 2026
PubMed

Insights

Researchers engineered fibroblast growth factor 2 (FGF2) variants with altered fibroblast growth factor receptor (FGFR) specificity. Single-amino acid changes successfully reprogrammed receptor selectivity, enabling tailored FGF/FGFR signaling network control.

Area of Science:

  • Molecular biology
  • Biochemistry
  • Signaling pathways

Background:

  • The fibroblast growth factor (FGF) family and its seven fibroblast growth factor receptor (FGFR) isoforms form complex signaling networks.
  • FGF2 has significant physiological roles and therapeutic potential, but its broad FGFR activation causes adverse effects.
  • Engineering FGF ligands for controlled FGFR isoform specificity is crucial for therapeutic applications.

Purpose of the Study:

  • To engineer FGF2 variants with altered FGFR isoform specificity.
  • To identify key residues in the FGFR-binding interface that determine receptor specificity.
  • To establish a framework for designing FGF ligands with tailored specificity.

Main Methods:

  • Utilized mRNA display-based deep mutational scanning (DMS) to engineer FGF2 variants.
  • Systematically evaluated residues within the FGFR-binding interface.
  • Assessed the FGFR isoform specificity of engineered FGF2 variants.

Main Results:

  • Successfully generated FGF2 variants with altered FGFR isoform specificity.
  • Demonstrated that FGFR isoform specificity is malleable and can be reprogrammed.
  • Identified single-amino acid substitutions as sufficient to alter receptor selectivity.

Conclusions:

  • Receptor selectivity in FGF2 is tunable.
  • Provided a method for rationally designing FGF ligands with specific FGFR isoform targeting.
  • Advanced the understanding and control of FGF/FGFR signaling networks.